Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Varicella zoster virus vaccine - Merck & Co

Drug Profile

Varicella zoster virus vaccine - Merck & Co

Alternative Names: Provarivax; V211; Varicella zoster virus vaccine live - Merck & Co; Variped; Varivax; Varivax II; Zostavax

Latest Information Update: 29 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Osaka University
  • Developer CSL; Merck & Co; sanofi pasteur MSD
  • Class Varicella vaccines; Viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Herpes zoster; Varicella zoster virus infections
  • Phase III Pneumococcal infections

Most Recent Events

  • 02 Apr 2019 Merck & Co completes a phase III trial in Varicella zoster virus infections (Prevention, In volunteers, In infants) in USA (SC) (NCT03239873)
  • 01 Mar 2019 Phase-III clinical trials in Varicella zoster virus infections (Prevention, In infants, In children, In adolescents, In adults) in Russia (SC) (NCT03843632)
  • 21 Feb 2019 Merck plans a phase III trial for Varicella zoster virus infections (Prevention) (NCT03843632)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top